Hosted on MSN28d
Bayer MRI contrast agent gadoquatrane meets goals in phase 3 trials
Bayer (OTCPK:BAYRY) said that phase 3 data on its experimental MRI contrast agent gadoquatrane met primary and secondary endpoints in phase 3 trials.The QUANTI studies examined gadoquatrane at a ...
Business Wire28d
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane ...
Pharmabiz25d
Bayer announces positive results of pivotal phase III QUANTI studies of gadoquatrane, an investigational GBCA for use in magnetic resonance imaging
Bayer, a global leader in radiology, announced positive topline results of the pivotal phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based ...
Morningstar24d
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
Bayer is advancing its pipeline. A significant milestone was achieved with its Phase III QUANTI clinical development program, which evaluated the investigational compound gadoquatrane. The first ...
PharmiWeb26d
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in Phase III studies
gadoquatrane met diagnostic efficacy endpoints in patients using a 60 percent lower gadolinium dose compared to macrocyclic gadolinium-based contrast agents dosed at 0.1 mmol Gd/body weight Reading, ...
Yahoo Finance29d
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
gadoquatrane met diagnostic efficacy endpoints in patients using a 60 percent lower gadolinium dose compared to macrocyclic gadolinium-based contrast agents dosed at 0.1 mmol Gd/kg body weight BERLIN, ...